Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia

Adrian Christopher Jaramillo, Isabelle Hubeek, Richard Broekhuizen, Marçal Pastor-Anglada, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos, Godefridus J. Peters

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These transporters are responsible for influx of cytarabine and reduced hENT1 expression is a major resistance mechanism in acute myeloid leukemia. We determined hENT1 and hCNT1 protein expression by immunocytochemistry in 50 diagnostic pediatric acute myeloid leukemia patient samples. All samples expressed hENT1 [9/43 (21%) low; 26/43 (60%) medium and 8/43 (19%) high] and hCNT1 [2/42 (5%) low; 35/42 (83%) medium and 5/42 (12%) high] at the cell membrane and cytoplasm. Statistical analysis showed a non-significant relationship between survival and transporter expression and in vitro drug sensitivity. In conclusion, the nucleoside transporters hENT1 and hCNT1 are broadly expressed in pediatric acute myeloid leukemia at diagnosis.

Original languageEnglish
Pages (from-to)1379-1388
Number of pages10
JournalNucleosides, Nucleotides and Nucleic Acids
Issue number10-12
Publication statusPublished - 2020


  • Acute myeloid leukemia (AML)
  • acute lymphoblastic leukemia (ALL)
  • bovine serum albumin (BSA)
  • cytarabine (Ara-C)
  • deoxynucleoside analogs (NAs)
  • human concentrative nucleoside transporter-1 (hCNT1)
  • human equilibrative nucleoside transporter-1 (hENT1)
  • phosphate buffered saline (PBS)

Cite this